Cut to Gavi's funding to impact our ability to protect children: Professor José Manuel Barroso
What was the agenda behind your recent India visit?
My recent visit to India reinforced the strong Gavi-India partnership and celebrated immunization progress since 2002. The current India-Gavi partnership represents a strong example of immunization collaboration within Gavi-supported countries. We are developing a roadmap for our collaboration beyond 2026, shifting towards targeted technical assistance, innovation partnerships, and knowledge sharing as India strengthens its global health leadership and Gavi donor role. Also, as part of our strategic partnership we will be supporting the Government of India to roll-out the HPV vaccine, in a push to eliminate cervical cancer in the country.
How would you rate Gavi's journey so far?
Over the past 25 years, Gavi has been highly impactful, immunizing over 1.1 billion children, preventing 18.8 million deaths, and halving child mortality in 78 lower-income countries. We also bolster global health security through health system support and vaccine stockpiles for Ebola, cholera, meningococcal and yellow fever vaccines. Our model relies on co-financing, with countries progressively contributing to their vaccine costs. We aim to expand our impact in the 2026-2030 period, protecting more people against more diseases faster.
How easy or difficult is it to sustain multilateral partnerships given Gavi is all about public-private global partnerships?
Maintaining political engagement and alignment across our diverse partners — governments, international organizations, manufacturers, civil society, and the private sector — is crucial for long-term sustainability, especially amid a complex funding environment.
What impact do you see of US pulling out as a contributor on Gavi's functioning?
While Gavi has not received any official notification regarding changes in US funding, recent reports are certainly extremely concerning. The US has been a long-standing partner with strong bipartisan support for over 25 years, including during the previous administration, and Congress recently approved $300 million for Gavi in the FY 2025 budget.
Any cut to Gavi's funding would have a devastating impact on our ability to protect children and keep our world safe. Gavi operates as an incredibly lean and efficient organisation, spending 97 cents of every dollar directly on life-saving programmes and delivering an estimated return of $54 in broader economic benefits for every $1 invested.
If you could specifically talk about some of the projects/initiatives that are likely to get disrupted.
The US currently contributes roughly 15% of Gavi's funding. A cut of this magnitude could translate, in rough terms, to 75 million fewer children protected during our 2026-2030 strategic period, leading potentially to 1.3 million more deaths from preventable illnesses. It would directly and negatively impact our capacity to protect the world against infectious disease threats through our global vaccine stockpiles (covering diseases like Ebola, cholera, meningitis, yellow fever) and our emergency response funds, which have proven crucial in recent events like the mpox outbreak.
Are there any alternatives that Gavi members are looking at to meet the overall funding requirement?
Gavi is focused on securing its target of at least $ 9 billion for the 2026-2030 period through contributions from its diverse range of partners. However, we recognize the current global funding environment is very complex and constrained. We have a broad base of sovereign donors, foundations, and private sector partners. Critically, implementing countries themselves are co-financing vaccine programmes at increasing levels, contributing nearly half of the costs in the upcoming strategic period. So far, 19 countries have already graduated entirely from Gavi support, and some, like India and Indonesia, have transitioned to become Gavi donors.
Given this broad existing base and the significant contributions already being made by implementing countries, it would be extremely difficult for other partners to make up a major shortfall should one occur.
Going forward, do you see any changes in the role that Gavi will be playing while helping needy countries?
Doing more, faster; enhanced health security (expanding stockpiles (such as adding mpox, in addition to Ebola, cholera, meningococcal and yellow fever vaccines); addressing climate change (nearly half our vaccine portfolio addresses diseases sensitive to climate shifts); tailored support (Adapting our support for countries as they develop); and leveraging innovation (Continuing to embrace AI, predictive analytics, and digital tools).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
3 hours ago
- Hindustan Times
3 major takeaways from nutritional intake data
... Next Story By Abhishek Jha , Roshan Kishore Jul 03, 2025 08:40 AM IST {{#userSubscribed}} {{/userSubscribed}} {{^userSubscribed}} {{/userSubscribed}} {{^userSubscribed}} {{/userSubscribed}} The National Sample Survey Office (NSSO) released its report on nutritional intake in India after more than a decade earlier this week. The latest report gives data for 2022-23 and 2023-24. To be sure, the nutritional intake surveys are essentially extrapolated numbers using quantities of food items consumed as seen in Household Consumption Expenditure Surveys (HCES). HT has already reported that the latest report largely shows an improvement in nutritional intake between 2011-12 and 2023-24. This key takeaway notwithstanding, there are some other interesting trends in the report. Here are three charts that summarise them. File picture {{^userSubscribed}} {{^usCountry}} {{/usCountry}} {{#usCountry}} {{/usCountry}} {{/userSubscribed}} {{^userSubscribed}} {{^usCountry}} {{/usCountry}} {{#usCountry}} {{/usCountry}} {{/userSubscribed}} SHARE THIS ARTICLE ON
Time of India
4 hours ago
- Time of India
Too much rice, too little nutrition: Telangana top in urban calorie intake; experts flag nutrition issues
HYDERABAD: Rice may be the comfort food in Telangana, but it's also quietly contributing to a calorie overload. In 2023-24, Telangana topped the nation in urban per capita calorie intake, with residents consuming an average of 2,455 calories a day. At the heart of this nutritional surge? A diet dominated by cereals-particularly rice-making up more than 43% of daily caloric intake, raising red flags for health experts. This revelation comes from the 'Nutritional Intake in India' report published by the Union ministry of statistics and programme implementation. At first glance, it may seem like a sign of abundance. But dig a little deeper, and experts warn it's a dietary pattern skewed heavily towards carbohydrates, with over 43% of daily calories coming from cereals, especially rice. You Can Also Check: Hyderabad AQI | Weather in Hyderabad | Bank Holidays in Hyderabad | Public Holidays in Hyderabad "The issue isn't just about how much we eat-it's about what we eat," says Dr Shiva Raju, senior consultant physician and diabetologist at KIMS Hospitals. "Obesity rates are rising across urban Telangana largely because of the over-dependence on rice. We need to rethink our food choices," Dr Raju said. The numbers speak for themselves. Urban Telangana residents, on average, consume 63.4 grams of ghee daily, and a staggering 70 grams statewide. While fats and oils add to overall calorie intake, it's the overconsumption of rice-often eaten in large, steaming servings-that's drawing concern from nutritionists. "Calorie intake in Telangana isn't necessarily excessive," clarifies professor Avula Laxmaiah, retired scientist from the National Institute of Nutrition. "But the quality of those calories is questionable," he says. Half of your diet must be veggies, fruit Ideally, half your plate should be vegetables and fruits, and the rest should be a mix of pulses and whole grains. Unfortunately, we're seeing a dominance of cereals, which impacts long-term health,' Laxmaiah says. Telangana's average urban intake even exceeds the sedentary threshold for both genders—significantly so when much of it is coming from starchy carbohydrates than nutrient-rich food. Bihar follows closely behind Telangana with an urban calorie intake of 2,453 calories. Chhattisgarh is next at 2,366 calories. Yet, Telangana stands apart not just for its calorie numbers but for the high percentage of those calories coming from rice. Beyond weight issues, health professionals are seeing a rise in vitamin deficiencies—particularly B12 and B-complex vitamins—despite people believing they 'eat enough.' 'People think three rice meals a day equals a good diet, but that's a myth,' Dr Raju adds. 'Nutrients must be absorbed properly, especially in patients with diabetes or high blood pressure. Without balance, even full plates can lead to empty nutrition,' he says.
The Hindu
13 hours ago
- The Hindu
Delhi High Court asks DGCI to decide on plea against licensing of weight-loss drugs
The Delhi High Court asked the Drug Controller General of India (DCGI) on Wednesday (July 2, 2025) to consult experts and relevant stakeholders in deciding a plea over drug combinations sold in the market for weight-loss treatment. A bench of Chief Justice D. K. Upadhyaya and Justice Tushar Rao Gedela asked the petitioner, Jitendra Chouksey, to give a representation to the DGCI, which was asked to decide the matter within three months. Mr. Chouksey, in his plea, alleged licenses issued for the use and sale of such drugs were not based on adequate data. The court, however, said the plea's concerns have to be first looked into and addressed by the DCGI. It allowed Mr. Chouksey to move the authority and bring relevant material and documents to its notice. Lack of clinical trials The plea raised concerns regarding the manner in which 'Glucagon-like peptide-1 receptor agonist (RA) drugs, specifically semaglutide, tirzepatide, and liraglutide, have been granted marketing approval in India for use in weight management and aesthetic treatments, despite limited safety data, lack of India-specific clinical trials, and absence of a robust pharmacovigilance or regulatory oversight mechanism.' It claimed that 'numerous studies have further highlighted the significant risks posed by these medications, including pancreatitis, gastrointestinal damage, thyroid and pancreatic cancers, cardiovascular complications, metabolic dysregulation, and optic neuropathy.' The plea said these drugs were originally developed and internationally approved for the treatment of Type 2 Diabetes Mellitus, with their primary therapeutic role being the regulation of glycemic levels. 'However, over the past few years, they have been repurposed and approved often through accelerated pathways for obesity treatment and chronic weight management, based largely on short-term efficacy trials,' it added. The plea said, 'In India, the CDSCO (Central Drugs Standard Control Organisation) has recently approved these drugs for weight- loss purposes without requiring large-scale clinical trials specific to Indian demographics or mandating post-marketing surveillance.' Mr. Chouksey said there is no evidence to suggest that these drugs have undergone rigorous safety evaluation within the Indian population. He cautioned that pharmaceutical companies, clinics, and digital wellness platforms are promoting the drug combinations as 'quick-fix' weight-loss solutions.
